Yi-Shen-Hua-Shi granule added to supportive care reduces proteinuria in IgA nephropathy: a multicenter randomized controlled trial.

In 30 seconds

This multicenter randomized controlled trial evaluated the efficacy of Yi-Shen-Hua-Shi granule in adults with IgA nephropathy and persistent proteinuria. The study found that after 8 weeks, the Yi-Shen-Hua-Shi group had a significant reduction in 24-hour proteinuria, with an estimated mean difference of approximately 340 mg compared to controls (p = 0.01).

Key findings

• Yi-Shen-Hua-Shi granule reduced 24-hour proteinuria by approximately 340 mg compared to best supportive care alone (p = 0.01).
• Patients with baseline proteinuria >1000 mg experienced a reduction of about 505 mg greater than controls (p = 0.01).
• No significant differences in estimated glomerular filtration rate or adverse events were observed between groups.
• The treatment was well-tolerated with stable renal function throughout the 8-week period.

Why it matters

The findings suggest that Yi-Shen-Hua-Shi granule may provide an effective adjunctive treatment for reducing proteinuria in patients with IgA nephropathy, particularly those with high baseline levels, potentially improving long-term outcomes.